OSL · MEDI.OL
Medistim ASA
NOK 307.00NOK 0.00 (0.0%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
Loading market information…
OSL · BGBIO.OL · NOK
Stock price, earnings
Quote as of Oct 29, 2025, 03:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
BerGenBio ASA’s quoted price sits in the lower half of its reported 52-week range, 92.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BerGenBio ASA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NOK 0.00 |
| Q4 2021 | May 24, 2022 | -NOK 0.78+3.7% vs estimate | NOK 774.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 307.00NOK 0.00 (0.0%)
Medistim ASA’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
NOK 10.52-NOK 0.02 (-0.19%)
Circio Holding ASA’s quoted price sits in the upper half of its reported 52-week range, 33.25% below the high.
NOK 25.80NOK 0.00 (0.0%)
Nordhealth AS’s quoted price sits in the lower half of its reported 52-week range, 32.81% below the high.
NOK 46.20-NOK 0.50 (-1.07%)
Photocure ASA’s quoted price sits in the lower half of its reported 52-week range, 42.11% below the high.
NOK 7.80+NOK 0.04 (+0.52%)
IDEX Biometrics ASA’s quoted price sits in the upper half of its reported 52-week range, 39.06% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
NOK 9.87NOK 0.00 (0.0%)
XXL ASA’s quoted price sits in the lower half of its reported 52-week range, 88.42% below the high.
NOK 0.07NOK 0.00 (0.0%)
PCI Biotech Holding ASA’s quoted price sits in the lower half of its reported 52-week range, 96.85% below the high.
